Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (361)	2/12/2000 4:38:00 AM
From: Neuroguy	Read Replies (4) \| Respond to of 427

Torben re GLIA (+ CLPA).. I am confused as to why you like GLIA. The chart looks 'green'?? In the last few months, you could have used a dartboard to choose your biotech. In the case of Glia, the dart hit the wall... The chart is ugly in the extreme. There is no pressing reason I can see to expect short-squeezing movement. They have no blockbuster drugs (Perceptin - I think not). What might you be seeing here that the shorts have missed? I'm curious. Speaking of blockbuster drugs, read the next issue of Business Week where CLPA's Aptosyn is mentioned in that light. The text is pasted at: ragingbull.com The shorts are suffering now and Murphy has been squirming on his hotline about being 'targeted by ignorant buyers" that he dared to try and take him out of his short position at $41. Closed at $44 1/8 today..:) Murphy derived his short position on CLPA based on a factually deficient Sturza report. That is the 5th time he recommended a short on CLPA based on Sturza, and the 5th time he was bulldozed.... Most shorts however seem to have stuck with CLPA expecting FDA rejection, while Morgan Stanley had to file a 10G to announce their 10% stake. So as much as CLPA has run up of late, the squeeze proper there has not yet begun. The shorts had 30% of the float and seem to have done little covering. The hardcopy of Business Week is out this weekend, and FDA approval is expected soon. Could still be a very nice squeeze play.